AngioJet rheolytic thrombectomy under superior vena cava filter protection for acute upper extremity deep vein thrombosis in patients with cancer: a single-center, retrospective analysis.

All 19 cancer patients with acute UEDVT achieved technical success (thrombus clearance >80%) with AngioJet thrombectomy under SVC filter protection.

• 19 patients (10 female; mean age 60.84 ± 11.30 years) treated between January 1, 2020 and October 1, 2025 at a single center.
• Technical success was defined as thrombus clearance rate >80%.
• All procedures achieved technical success.

No severe intraoperative adverse events and no new symptomatic pulmonary embolism occurred.

• No major bleeding occurred intraoperatively.
• Procedures used an 8-Fr AngioJet system (Boston Scientific) with a retrievable SVC filter in place.
• Retrospective, single-center design with 19 patients.

Limb swelling decreased substantially by the second postoperative day.

• Mean circumference 10 cm above the elbow was 29.83 ± 2.20 cm before surgery.
• It decreased to 26.98 ± 2.0 cm on postoperative day 2.

All patients had secondary UEDVT with a history of malignancy, and most had a history of central venous catheterization.

• All 19 patients had secondary UEDVT and a history of malignant tumors.
• 14 patients (73.7%) had a history of central venous catheterization.

During 6-month follow-up, one patient had recurrent DVT and another had an asymptomatic mural thrombus.

• One patient with advanced lung cancer developed upper limb swelling on postoperative day 136, confirmed by ultrasound as DVT recurrence.
• Another patient had an asymptomatic mural thrombus found on ultrasound on postoperative day 28.